Literature DB >> 3968641

Amphetamine attenuates the stimulated release of dopamine in vivo.

W G Kuhr, A G Ewing, J A Near, R M Wightman.   

Abstract

Carbon-fiber voltammetric electrodes have been used to measure the release of dopamine in the caudate nucleus of an anesthetized rat. Release is induced by electrical stimulation of the medial forebrain bundle. The amplitude of the observed release is attenuated by i.p. injection of amphetamine. A similar attenuation is induced by reserpine; however, at a slower rate. The combined regimen of amphetamine (1 or 10 mg/kg) and electrical stimulation does not deplete striatal dopamine levels and thus the decreased release of dopamine is not a result of depleted dopamine stores. Benztropine (25 mg kg-1) is able to cause a short term inhibition of the action of amphetamine (1 mg kg-1). The dopamine agonist pergolide (0.5 mg kg-1) does not affect the stimulated release. Haloperidol (1.0 mg kg-1) increases the amount of DA release, but is unable to attenuate the inhibition caused by amphetamine. Thus, it appears that the actions induced by amphetamine are a result of interaction with the neuronal uptake carrier and subsequent transport of dopamine from a functional to nonfunctional pool. In isolated striatal synaptic vesicles, amphetamine is found to block dopamine uptake and induce its release. This in vitro evidence provides a possible mechanism for the observed in vivo actions of amphetamine.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3968641

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  10 in total

Review 1.  Phasic dopamine release in appetitive behaviors and drug addiction.

Authors:  Matthew J Wanat; Ingo Willuhn; Jeremy J Clark; Paul E M Phillips
Journal:  Curr Drug Abuse Rev       Date:  2009-05

2.  Amphetamine augments action potential-dependent dopaminergic signaling in the striatum in vivo.

Authors:  Eric S Ramsson; Daniel P Covey; David P Daberkow; Melissa T Litherland; Steven A Juliano; Paul A Garris
Journal:  J Neurochem       Date:  2011-05-03       Impact factor: 5.372

3.  High doses of amphetamine augment, rather than disrupt, exocytotic dopamine release in the dorsal and ventral striatum of the anesthetized rat.

Authors:  Eric S Ramsson; Christopher D Howard; Dan P Covey; Paul A Garris
Journal:  J Neurochem       Date:  2011-08-25       Impact factor: 5.372

4.  Amphetamine distorts stimulation-dependent dopamine overflow: effects on D2 autoreceptors, transporters, and synaptic vesicle stores.

Authors:  Y Schmitz; C J Lee; C Schmauss; F Gonon; D Sulzer
Journal:  J Neurosci       Date:  2001-08-15       Impact factor: 6.167

Review 5.  Presynaptic control of serotonin on striatal dopamine function.

Authors:  Sylvia Navailles; Philippe De Deurwaerdère
Journal:  Psychopharmacology (Berl)       Date:  2010-10-16       Impact factor: 4.530

6.  Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's disease.

Authors:  Tomas Björklund; Thomas Carlsson; Erik Ahlm Cederfjäll; Manolo Carta; Deniz Kirik
Journal:  Brain       Date:  2010-02-02       Impact factor: 13.501

7.  Amphetamine augments vesicular dopamine release in the dorsal and ventral striatum through different mechanisms.

Authors:  Alicia J Avelar; Steven A Juliano; Paul A Garris
Journal:  J Neurochem       Date:  2013-03-06       Impact factor: 5.372

8.  Amphetamine paradoxically augments exocytotic dopamine release and phasic dopamine signals.

Authors:  D P Daberkow; H D Brown; K D Bunner; S A Kraniotis; M A Doellman; M E Ragozzino; P A Garris; M F Roitman
Journal:  J Neurosci       Date:  2013-01-09       Impact factor: 6.167

Review 9.  Ventral Tegmental Area Afferents and Drug-Dependent Behaviors.

Authors:  Idaira Oliva; Matthew J Wanat
Journal:  Front Psychiatry       Date:  2016-03-07       Impact factor: 4.157

10.  Amphetamine elicits opposing actions on readily releasable and reserve pools for dopamine.

Authors:  Dan P Covey; Steven A Juliano; Paul A Garris
Journal:  PLoS One       Date:  2013-05-03       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.